Nuvalent/NUVL

$88.99

3.84%
-
1D1W1MYTD1YMAX

About Nuvalent

Nuvalent, Inc. is a clinical-stage biopharmaceutical company, which is focused on creating precisely targeted therapies for patients with cancer. Its lead product candidate, NVL-520 is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. Its second lead product candidate, NVL-655, is a brain-penetrant ALK-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first, second, and third generation ALK inhibitors. The Company’s product candidate also includes NVL-330, is a brain-penetrant HER2-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20, treating brain metastases, and avoiding treatment-limiting adverse events, including due to off-target inhibition of wild-type EGFR.

Ticker

NUVL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

James Porter

Employees

89

Headquarters

Cambridge, United States

Nuvalent Metrics

BasicAdvanced
$5.47B
Market cap
-
P/E ratio
-$2.03
EPS
-
Beta
-
Dividend rate

What the Analysts think about Nuvalent

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
4.67% downside
High $100.00
Low $68.00
$88.99
Current price
$84.83
Average price target

Nuvalent Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-33.6M
15.86%
Profit margin
0%
-

Nuvalent Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.29%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.49
-$0.44
-$0.51
-$0.59
-
Expected
-$0.43
-$0.51
-$0.53
-$0.58
-$0.60
Surprise
14.06%
-14.1%
-3.15%
1.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Nuvalent stock

Buy or sell Nuvalent stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing